Literature DB >> 26474302

The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM.

Sofie H Mooij1, Daniëla K van Santen, Ronald B Geskus, Marianne A B van der Sande, Roel A Coutinho, Ineke G Stolte, Peter J F Snijders, Chris J L M Meijer, Arjen G C L Speksnijder, Henry J C de Vries, Audrey J King, Arne van Eeden, Maarten F Schim van der Loeff.   

Abstract

OBJECTIVES: A large portion of anogenital cancers is caused by high-risk human papillomavirus (hrHPV) infections, which are especially common in HIV-infected men. We aimed to compare the incidence and clearance of anal and penile hrHPV infection between HIV-infected and HIV-negative MSM.
DESIGN: Analyses of longitudinal data from a prospective cohort study.
METHODS: MSM aged 18 years or older were recruited in Amsterdam, the Netherlands, and followed-up semi-annually for 24 months. At each visit, participants completed risk-factor questionnaires. Anal and penile self-samples were tested for HPV DNA using the SPF10-PCR DEIA/LiPA25 system. Effects on incidence and clearance rates were quantified via Poisson regression, using generalized estimating equations to correct for multiple hrHPV types.
RESULTS: Seven hundred and fifty MSM with a median age of 40 years (interquartile 35-48) were included in the analyses, of whom 302 (40%) were HIV-infected. The incidence rates of hrHPV were significantly higher in HIV-infected compared with HIV-negative MSM [adjusted incidence rate ratio (aIRR) 1.6; 95% confidence interval (CI) 1.3-2.1 for anal and aIRR 1.4; 95%CI 1.0-2.1 for penile infection]. The clearance rate of hrHPV was significantly lower for anal [adjusted clearance rate ratio (aCRR) 0.7; 95%CI 0.6-0.9], but not for penile infection (aCRR 1.3; 95%CI 1.0-1.7). HrHPV incidence or clearance did not differ significantly by nadir CD4 cell count.
CONCLUSION: Increased anal and penile hrHPV incidence rates and decreased anal hrHPV clearance rates were found in HIV-infected compared with HIV-negative MSM, after adjusting for sexual behavior. Our findings suggest an independent effect of HIV infection on anal hrHPV infections.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474302     DOI: 10.1097/QAD.0000000000000909

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Incidence and time trends of anal cancer among people living with HIV in Australia.

Authors:  Fengyi Jin; Claire M Vajdic; Matthew Law; Janaki Amin; Marina van Leeuwen; Skye McGregor; I Mary Poynten; David J Templeton; Andrew E Grulich
Journal:  AIDS       Date:  2019-07-01       Impact factor: 4.177

2.  Evaluating the Jaccard Similarity Index as a Persistence Measure of Multiple Anal Human Papillomavirus Among Nigerian Men Who Have Sex With Men.

Authors:  Rebecca G Nowak; Søren M Bentzen; Lisa M Schumaker; Nicholas P Ambulos; Nicaise Ndembi; Wuese Dauda; Andrew Mitchell; Trevor J Mathias; Trevor A Crowell; Stefan D Baral; William A Blattner; Manhattan E Charurat; Joel M Palefsky; Kevin J Cullen
Journal:  Sex Transm Dis       Date:  2022-04-01       Impact factor: 2.830

3.  Social networks, high-risk anal HPV and coinfection with HIV in young sexual minority men.

Authors:  Kayo Fujimoto; Aditya Khanna; Alan G Nyitray; Jacky Kuo; Jing Zhao; Lu-Yu Hwang; Elizabeth Chiao; Anna R Giuliano; John A Schneider
Journal:  Sex Transm Infect       Date:  2022-02-19       Impact factor: 4.199

4.  Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly Black Men Who Have Sex With Men, Houston, Texas.

Authors:  Alan G Nyitray; Kayo Fujimoto; Jing Zhao; Anna R Giuliano; John A Schneider; Lu-Yu Hwang
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

Review 5.  Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis.

Authors:  Eleanor M King; Soonita Oomeer; Richard Gilson; Andrew Copas; Simon Beddows; Kate Soldan; Mark Jit; W John Edmunds; Pam Sonnenberg
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

6.  Modeling the Mechanisms by Which HIV-Associated Immunosuppression Influences HPV Persistence at the Oral Mucosa.

Authors:  Meghna Verma; Samantha Erwin; Vida Abedi; Raquel Hontecillas; Stefan Hoops; Andrew Leber; Josep Bassaganya-Riera; Stanca M Ciupe
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

7.  What explains anorectal chlamydia infection in women? Implications of a mathematical model for test and treatment strategies.

Authors:  Janneke C M Heijne; Geneviève A F S van Liere; Christian J P A Hoebe; Johannes A Bogaards; Birgit H B van Benthem; Nicole H T M Dukers-Muijrers
Journal:  Sex Transm Infect       Date:  2016-12-16       Impact factor: 3.519

8.  Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status.

Authors:  Katharine J Looker; Minttu M Rönn; Patrick M Brock; Marc Brisson; Melanie Drolet; Philippe Mayaud; Marie-Claude Boily
Journal:  J Int AIDS Soc       Date:  2018-06       Impact factor: 5.396

9.  Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women.

Authors:  Evy Yunihastuti; Nipat Teeratakulpisarn; Wifanto Saditya Jeo; Hanny Nilasari; Lisnawati Rachmadi; I Ketut Agus Somia; Made Dewi Dian Sukmawati; Komang Agus Trisna Amijaya; Ilias A Yee; Nany Hairunisa; Piranun Hongchookiat; Deondara Trachunthong; Tippawan Pankam; Siriporn Nonenoy; Reshmie Ramautarsing; Iskandar Azwa; Tuti P Merati; Praphan Phanuphak; Nittaya Phanuphak; Joel M Palefsky
Journal:  AIDS       Date:  2020-11-01       Impact factor: 4.632

10.  Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions.

Authors:  Attila T Lorincz; Mayura Nathan; Caroline Reuter; Rhian Warman; Mohamed A Thaha; Michael Sheaff; Natasa Vasiljevic; Amar Ahmad; Jack Cuzick; Peter Sasieni
Journal:  Oncotarget       Date:  2017-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.